SanBio : Presentation for Financial Results for the Fiscal Year Ending Jan.31, 2022
March 11, 2022 at 01:16 am EST
Share
Financial Results
for the Fiscal Year Ending January 31, 2022
SanBio Company Limited
(TSE Mothers: 4592)
March 11, 2022
1
Table of Contents
Financial Results
SB623 Approval in Japan and Sales Structure After Approval
Toward Maximizing Corporate Value
Q&A
2
Copyright（C） 2022 All Rights Reserved, SanBio Company Limited
1. Financial Results
3
Copyright（C） 2022 All Rights Reserved, SanBio Company Limited
Consolidated Income Statement
R&D expenses rose on increased spending related to manufacturing toward approval filing of
SB623 chronic TBI program in Japan.
FY2021.1
FY2022.1
(B)-(A)
FY2022.1
Results (A)
Results (B)
Forecast
Million Yen
Revenue
-
-
-
-
R&D
4,071
4,955
884
3,820
expenses
Operating expenses
5,801
6,618
817
5,786
Operating income
-5,801
-6,618
-817
-5,786
Net income
-3,385
-4,675
-1,290
-5,877
Yen/US$ exchange
106.34
110.73
-
110.00
rate
4
Copyright（C） 2022 All Rights Reserved, SanBio Company Limited
Consolidated Balance Sheet
Cash & cash equivalents and net assets declined. Began procuring funds in February 2022 to fortify
financial base in light of future business development.
As of January 31,
As of January 31,
(B)-(A)
2021 (A)
2022 (B)
Million yen
Cash & cash
12,480
4,557
-7,923
equivalents
Supplies
444
467
23
Current assets
13,131
5,351
-7,780
Non-current assets
211
159
-52
Total assets
13,343
5,510
-7,833
Current liabilities
2,469
1,461
-1,008
Non-current liabilities
2,525
2,012
-513
Total liabilities
4,994
3,473
-1,521
Net assets
8,349
2,037
-6,312
Total liabilities and net
13,343
5,510
-7,833
assets
5
Copyright（C） 2022 All Rights Reserved, SanBio Company Limited
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
SanBio Co. Ltd. published this content on 11 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 March 2022 06:15:10 UTC.
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).
SANBIO COMPANY LIMITED 
